Pharmaceutical

EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi

The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.

Jul 30, 2024 - 04:00
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
Read the original article

Tags:

Previous Article

CHMP backs Boehringer’s Spevigo for preventing rare psoriasis flare-ups

Next Article

Attralus set for amyloidosis asset’s European orphan designations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Could private equity be the future of private practice? A new lobbying group thinks so

STAT+: Could private equity be the future of private pr...

Jan 16, 2024

STAT+: The FDA is testing new nutrition labels on the front of food packages

STAT+: The FDA is testing new nutrition labels on the f...

Jun 20, 2023

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab by Bristol-Myers Squibb for Metastatic Trans...

Aug 30, 2023